title: Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
abstract: The BCR-ABL kinase inhibitor, imatinib mesylate, is the front-line treatment for chronic myeloid leukemia, but the emergence of imatinib resistance has led to the search for alternative drug treatments. There is a pressing need, therefore, to develop and test novel drugs. Natural products including plants, microorganisms, and halobios provide rich resources for discovery of anticancer drugs. In this article, we demonstrate that emodin inhibited the growth of K562 cells harboring BCR-ABL in vitro and in vivo, and induced abundant apoptosis, which was correlated with the inhibition of PETN/PI3K/Akt level and deletion of BCR-ABL. These findings suggest that emodin is a promising agent to kill K562 cells harboring BCR-ABL.
authors.affiliation: 1 Yongchuan Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Chun-Guang
authors.initials: CG
authors.lastname: Wang
authors.affiliation: 2 Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Liang
authors.initials: L
authors.lastname: Zhong
authors.affiliation: 1 Yongchuan Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Yong-Li
authors.initials: YL
authors.lastname: Liu
authors.affiliation: 1 Yongchuan Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: Shi
authors.affiliation: 1 Yongchuan Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Long-Qin
authors.initials: LQ
authors.lastname: Shi
authors.affiliation: 1 Yongchuan Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Zeng
authors.affiliation: 1 Yongchuan Hospital, Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Bei-Zhong
authors.initials: BZ
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001688:Biological Products / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004642:Emodin / Q000494:pharmacology*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate / Q000494:pharmacology; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D019869:Phosphatidylinositol 3-Kinases; D016044:Fusion Proteins, bcr-abl; D051057:Proto-Oncogene Proteins c-akt; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D004642:Emodin
keywords: BCR-ABL; K562 cells; PI3K-AKT; PTEN; emodin